• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: COOK IRELAND LTD ZILVER FLEX 35 VASCULAR SELF-EXPANDING STENT; NIO STENT, ILIAC

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

COOK IRELAND LTD ZILVER FLEX 35 VASCULAR SELF-EXPANDING STENT; NIO STENT, ILIAC Back to Search Results
Catalog Number UNKNOWN
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Restenosis (4576)
Event Type  Injury  
Manufacturer Narrative
Pma k #p050017/s006.Investigation is still pending, a follow up mdr will be submitted to include the investigation conclusions.
 
Event Description
Fransson, 2023, randomized clinical trial comparing drug eluting stent zilver ptx® versus bare metal stent zilver flex® for treatment of lesions in femoral and popliteal arteries in chronic limb threatening ischemia.Patients presenting with clti scheduled for endovascular treatment of fp lesions were randomly assigned by blinded envelopes 1:1 in a single blinded, parallel group design to des or bms after lesion crossing.Primary endpoints were target lesion revascularization (tlr) at 12 and 24 months and primary patency at 12 and 24 months.Secondary endpoints were technical success (ts), clinical success, secondary patency at 12 and 24 months, limb salvage, serious adverse events (sae) at 24 month and survival at five years.This file was opened to capture the occurrence of predischarge restenosis in the zilver flex group.Require intervention/additional procedures.
 
Event Description
Supplemental report is being submitted due to the completion of the investigation on 01-dec-2023.
 
Manufacturer Narrative
Pma/510(k) #p050017/s006.Device evaluation: the device evaluation could not be completed as the device or photographic evidence of the device was not returned for evaluation.With the information provided, a document-based investigation was conducted.This file was created from the attached literature paper ¿fransson, 2023, randomized clinical trial comparing drug eluting stent zilver ptx® versus bare metal stent zilver flex® for treatment of lesions in femoral and popliteal arteries in chronic limb threatening ischemia.¿ it is related to (b)(4) (emdr 3001845648-2023-00476 ) and (b)(4) (emdr 3001845648-2023-00481) and captures 01 occurrence of predischarge restenosis in the bms zilver flex group.Manufacturing records review: prior to distribution all zilver flex devices are subjected to a visual inspection and functional inspection to ensure device integrity.Manufacturing records review could not be completed as the lot number is unknown.Instructions for use and label: it should be noted that the instructions for use (ifu0058) lists restenosis of the stented artery as potential adverse event.There is no evidence to suggest the user did not follow the ifu or label.Image review : an image was not returned for evaluation.Root cause analysis a definitive root cause could not be determined from the available information.A possible root cause could be attributed to the patients pre existing condition.From the available information it is known that patients baseline characteristics included chronic limb threatening ischemia, lesions in the sfa and first part of the pa, diabetes mellitus, chronic kidney disease, active smoking, cardiovascular disease and cerebrovascular disease.It is possible that patients pre-existing conditions caused or contributed to the event of predischarge restenosis.As previously noted, restenosis of a stented artery is listed as known potential adverse event within the ifu and is a common adverse event of endovascular procedures that can be caused by obstruction to the vessel.Confirmation of complaint: complaint is confirmed based on customer testimony and/or rep testimony.Summary of investigation the complaint was raised from literature paper ¿fransson, 2023, randomized clinical trial comparing drug eluting stent zilver ptx® versus bare metal stent zilver flex® for treatment of lesions in femoral and popliteal arteries in chronic limb threatening ischemia¿.According to the initial reporter, patients presenting with clti scheduled for endovascular treatment of fp lesions were randomly assigned by blinded envelopes1:1 in a single blinded, parallel group design to des or bms after lesion crossing.Primary endpoints were target lesion revascularization (tlr) at 12 and 24 months and primary patency at 12 and 24 months.Secondary endpoints were technical success (ts), clinical success, secondary patency at 12 and 24 months, limb salvage, serious adverse events (sae) at 24 month and survival at five years.This file was opened to capture the occurrence of predischarge restenosis in the bms zilver flex group.Confirmed quantity of (b)(4) devices, confirmed used.According to the article, it is known that in hospital technical failures were by protocol subject to corrective retreatment before discharge at the discretion of the interventionist.As per clinical input, the patients would have required intervention/additional procedures.Investigation findings conclude a possible root cause of the patients pre existing conditions which included chronic limb threatening ischemia.As previously noted, restenosis of a stented artery is listed as known potential adverse event within the ifu and is a common adverse event of endovascular procedures that can be caused by obstruction to the vessel.Complaints of this nature will continue to be monitored for potential emerging trends.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ZILVER FLEX 35 VASCULAR SELF-EXPANDING STENT
Type of Device
NIO STENT, ILIAC
Manufacturer (Section D)
COOK IRELAND LTD
o halloran road
limerick
Manufacturer (Section G)
COOK IRELAND LTD
o halloran road
national technology park
limerick
Manufacturer Contact
sinead o'leary
o halloran road
national technology park
limerick 
MDR Report Key17161743
MDR Text Key317452204
Report Number3001845648-2023-00480
Device Sequence Number1
Product Code NIO
Combination Product (y/n)N
Reporter Country CodeSW
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature
Reporter Occupation Other
Type of Report Initial,Followup
Report Date 12/01/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberUNKNOWN
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Was the Report Sent to FDA? No
Distributor Facility Aware Date05/22/2023
Event Location Hospital
Initial Date Manufacturer Received 05/22/2023
Initial Date FDA Received06/20/2023
Supplement Dates Manufacturer Received05/22/2023
Supplement Dates FDA Received12/18/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age75 YR
Patient SexMale
-
-